ENVISION DIAGNOSTICS RAISES SERIES A ROUND

ENVISION DIAGNOSTICS RAISES SERIES A ROUND

ExSight Ventures ("EV") is pleased to announce our continued involvement and additional investment in Envision Diagnostics, Inc. ("Envision"). EV joined existing investors and new investors in Envision’s recent Series A financing. Envision is developing diagnostic devices that capture eye exams digitally. Envision's all-in-one box solution enables faster, cheaper, and more accurate readings of an eye exam. The Envision device will translate into higher quality and more efficient eye exams.
 
EV has committed additional capital in this Series A financing. Proceeds from this Series A round will fund the development of the company's Version 4 Instrument and allow Envision to execute its FDA strategy.
 
Envision recently successfully completed a clinical trial that compared Envision’s results to the standard of care.
 
Envision continues to develop and iterate on its current prototype at Dr. Rahhal's clinic. Envision's data collection and standardization will revolutionize the standard of care for ophthalmology patients "by enabling consistent, reproducible testing and robust reference ranges that facilitate identification of abnormalities."
 
Envision's automation will reshape ophthalmology by decreasing cost, increasing efficiency, improving quality, and standardizing eye exams.
 
We expect strong demand and a steep adoption curve based on clinical insights by the ExSight team and others. Funding was the single biggest challenge facing the company. With this issue now resolved, we are confident in Envision's ability to deliver on its promise of revolutionizing eye care.